RYTHM, Inc.RYMEarnings & Financial Report
RYTHM, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for rare genetic endocrine and metabolic disorders with high unmet medical needs. It primarily operates in the U.S. market, targeting pediatric and adult patient segments that lack standard effective treatment options.
Revenue
$-7.5M
Gross Profit
$-1.6M
Operating Profit
N/A
Net Profit
$-24.4M
Gross Margin
21.2%
Operating Margin
N/A
Net Margin
324.4%
YoY Growth
-762.7%
EPS
$-24.26
RYTHM, Inc. Q4 FY2024 Financial Summary
RYTHM, Inc. reported revenue of $-7.5M (down 762.7% YoY) for Q4 FY2024, with a net profit of $-24.4M (324.4% margin).
Key Financial Metrics
| Total Revenue | $-7.5M |
|---|---|
| Net Profit | $-24.4M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2024 |
RYTHM, Inc. Annual Revenue by Year
RYTHM, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $17.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $17.3M |
| 2024 | $18.0K |
| 2023 | $15.1M |
| 2022 | $58.3M |
RYTHM, Inc. Quarterly Revenue & Net Profit History
RYTHM, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $10.7M | +242.0% | $-13.6M | -127.6% |
| Q3 FY2025 | $4.0M | +109.0% | $-10.7M | -263.8% |
| Q2 FY2025 | $2.0M | -31.8% | $-7.4M | -360.4% |
| Q1 FY2025 | $538.0K | -79.3% | $-1.6M | -302.2% |
| Q4 FY2024 | $-7.5M | -762.7% | $-24.4M | 324.4% |
| Q3 FY2024 | $1.9M | -38.4% | $-18.7M | -964.4% |
| Q2 FY2024 | $3.0M | -40.9% | $-3.0M | -99.3% |
| Q1 FY2024 | $2.6M | -55.2% | $4.2M | 163.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M | $3.0M | $1.9M | $-7.5M | $538000 | $2.0M | $4.0M | $10.7M |
| YoY Growth | -55.2% | -40.9% | -38.4% | -762.7% | -79.3% | -31.8% | 109.0% | 242.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $40.6M | $39.4M | $39.0M | $54.0M | $45.6M | $69.5M | $115.2M | $106.7M |
| Liabilities | $46.1M | $30.9M | $33.5M | $25.9M | $18.8M | $48.5M | $103.4M | $93.7M |
| Equity | $-5.5M | $8.5M | $5.5M | $28.1M | $26.8M | $21.0M | $11.7M | $13.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.0M | $-1.8M | $-1.4M | $-5.3M | $-6.7M | $-8.4M | $-5.4M | $-3.0M |